MI Arrowhead Publishers and Conferences
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     


Molecular Interventions 6:253-256, (2006)
© American Society for Pharmacology and Experimental Therapeutics
10.1124/mi.6.5.6
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Carroll, H. P.
Right arrow Articles by Gadina, M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Carroll, H. P.
Right arrow Articles by Gadina, M.

Viewpoint

Immunodeficiency Is A Tough Nut to CRAC: The Importance of Calcium Flux in T Cell Activation

Helen P. Carroll, Benjamin B.A. McNaull and Massimo Gadina

Division of Infection and Immunity, Center for Cancer Research and Cell Biology, Queen’s University Belfast

SUMMARY

Severe Combined Immunodeficiency (SCID) is a rare primary immunodeficiency disease often characterized by a block in T cell development, which may also affect the normal development of B cells and NK cells. Several different mutations are known to give rise to SCID, and multiple genes are involved. Consequently, there are several different forms of SCID, which can be classified according to the metabolic and cellular defects that impede normal lymphocyte function. The two most prevalent forms of SCID are X-linked SCID and adenosine deaminase (ADA) deficiency SCID, together accounting for approximately 70–80% of disease cases. Other genetic abnormalities associated with this syndrome range from defective T cell receptor rearrangement to non-functional signaling molecules. Recently, a new genetic defect has been described in which mutations in a key component of Ca2+ release activated–channels (CRAC) result in T lymphocyte malfunction.




This article has been cited by other articles:


Home page
J. Biol. Chem.Home page
I. Derler, M. Fahrner, O. Carugo, M. Muik, J. Bergsmann, R. Schindl, I. Frischauf, S. Eshaghi, and C. Romanin
Increased Hydrophobicity at the N Terminus/Membrane Interface Impairs Gating of the Severe Combined Immunodeficiency-related ORAI1 Mutant
J. Biol. Chem., June 5, 2009; 284(23): 15903 - 15915.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
ASPET Journals Pharmacological Reviews Drug Metabolism and Disposition
Molecular Interventions Molecular Pharmacology J Pharmacology and Exp Therapeutics
Copyright © 2006 by the American Society for Pharmacology and Experimental Therapeutics.